loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Phytex Scopolamine

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,365Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zydus Lifesciences gets USFDA nod to market Scopolamine transdermal system
    Zydus Lifesciences gets USFDA nod to market Scopolamine transdermal system

    30 Aug 2024

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-lifesciences-gets-usfda-nod-to-market-scopolamine-transdermal-system/articleshow/112925108.cms

    ECONOMICTIMES
    30 Aug 2024
    Share Share
    Zydus`s Generics Scopolamine Receives Approval in US
    Zydus`s Generics Scopolamine Receives Approval in US

    29 Aug 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217893

    FDA
    29 Aug 2024
    Share Share
    Defender gets CRL from FDA on motion sickness nasal gel
    Defender gets CRL from FDA on motion sickness nasal gel

    31 Jan 2024

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/fda-rejects-defenders-motion-sickness-nasal-gel-candidate#:~:text=A%20nasal%20gel%20version%20of%20the%20motion%20sickness%20drug%20scopolamine,and%20vomiting%20induced%20by%20motion.

    Kevin Dunleavy FIERCE PHARMA
    31 Jan 2024
    Share Share
    Defender Receives CRL from the USFDA for its Intranasal Scopolamine
    Defender Receives CRL from the USFDA for its Intranasal Scopolamine

    30 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/01/30/2820312/0/en/Defender-Pharmaceuticals-Receives-Complete-Response-Letter-from-the-U-S-Food-and-Drug-Administration-for-its-Intranasal-Scopolamine-DPI-386-New-Drug-Application-for-the-Prevention-.html

    GLOBENEWSWIRE
    30 Jan 2024
    Share Share
    FDA Accepts Defender™ New Drug Application for Intranasal Scopolamine Gel
    FDA Accepts Defender™ New Drug Application for Intranasal Scopolamine Gel

    26 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/26/2749419/0/en/FDA-Accepts-Defender-Pharmaceuticals-New-Drug-Application-for-Intranasal-Scopolamine-Gel.html

    GLOBENEWSWIRE
    26 Sep 2023
    Share Share
    Defender Announces Submission of NDA to FDA with Intranasal Scopolamine
    Defender Announces Submission of NDA to FDA with Intranasal Scopolamine

    26 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/26/2711490/0/en/Defender-Pharmaceuticals-Announces-Submission-of-New-Drug-Application-to-FDA-with-Intranasal-Scopolamine-for-Prevention-of-Nausea-and-Vomiting-Induced-by-Motion-in-Adults.html

    GLOBENEWSWIRE
    26 Jul 2023
    Share Share